The Centers for Medicare & Medicaid Services yesterday proposed that Medicare cover monoclonal antibodies that target amyloid to treat Alzheimer’s disease for beneficiaries enrolled in qualifying clinical trials. The Food and Drug Administration last June approved the first such Alzheimer’s treatment, Biogen’s Aduhelm (aducanumab), using its accelerated approval pathway. 

“This proposed National Coverage Determination is the result of robust evidence analysis conducted through a thorough review process that found while there may be the potential for promise with this treatment, there is also the potential for harm to patients,” said CMS Chief Medical Officer Lee Fleisher, M.D. “This harm may range from headaches, dizziness, and falls, to other potentially serious complications such as brain bleeds.”

Under the proposed NCD, Medicare would cover the drug, related services and other routine costs, which may include PET scans if required by a trial protocol, CMS said. The agency will accept comments on the proposed NCD for 30 days.

Related News Articles

Headline
The federal government shut down Oct. 1 following a failed Senate vote on the House-passed continuing resolution to fund the government by midnight Sept. 30.…
Headline
The AHA Sept. 29 sent recommendations to the Department of Health and Human Services and the Centers for Medicare & Medicaid Services to help ensure…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 26 that average premiums for Medicare Advantage and Part D would decline slightly in 2026.…
Headline
The AHA expressed support Sept. 22 to House and Senate sponsors of the Medicare Advantage Prompt Pay Act (H.R. 5454/S. 2879), legislation that would apply a…
Headline
The Centers for Medicare & Medicaid Services Sept. 18 released a final rule on policy and technical changes to Medicare Advantage, the Medicare…
Headline
The AHA submitted a statement Sept. 17 for a House Ways and Means Committee markup session on a series of health care and other bills. Specifically, the AHA…